Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Sette, Giovanni ^b   Fecchi, Katia ^a   Salvati, Valentina ^a   Lotti, Fiorenza ^a   Pilozzi, Emanuela ^c   Duranti, Enrico ^c   Biffoni, Mauro ^a   Pagliuca, Alfredo ^a   Martinetti, Daniela ^d   Memeo, Lorenzo ^d   Milella, Michele ^b   De Maria, Ruggero ^b   Eramo, Adriana ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Mediterranean Institute of Oncology   (Italy)

Author keywords

Mek inhibition; Melanospheres; Metastatic Melanoma; Target therapy

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 AMINOPURINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 IODOTUBERCIDIN; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; AG 1288; AG 370; ALPHA (3,5 DICHLOROBENZYLIDENE) 3 PYRIDYLACETONITRILE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; B RAF KINASE; BML 257; CISPLATIN; DACARBAZINE; FASUDIL; KENPAULLONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2 AMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; PACLITAXEL; PICEATANNOL; ROSCOVITINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MELANOSPHERE; METASTATIC MELANOMA; MOUSE; MUTATION; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; APOPTOSIS; BENZAMIDES; DIPHENYLAMINE; FEMALE; MAP KINASE KINASE KINASES; MELANOMA; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; PROTEIN KINASE INHIBITORS; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887508908     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-91     Document Type: Article

References (53)

1. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 10 29 10.3322/caac.20138 22237781
2. Management of cutaneous melanoma. Tsao H, Atkins MB, Sober AJ, N Engl J Med 2004 351 998 1012 10.1056/NEJMra041245 15342808 (Pubitemid 39166263)
3. Malignant melanoma in the 21st century: the emerging molecular landscape. Sekulic A, Haluska P Jr, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, Swanson DL, et al. Mayo Clin Proc 2008 83 825 846 10.4065/83.7.825 18613999 (Pubitemid 351948695)
4. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM, Cancer Res 2006 66 9339 9344 10.1158/0008-5472.CAN-06-3126 16990346 (Pubitemid 44623625)
5. Current management and novel agents for malignant melanoma. Lee B, Mukhi N, Liu D, J Hematol Oncol 2012 5 3 10.1186/1756-8722-5-3 22333219
6. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. Robert C, Thomas L, Bondarenko I, O'Day S, DJ M, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. N Engl J Med 2011 364 2517 2526 10.1056/NEJMoa1104621 21639810
7. Improved survival with ipilimumab in patients with metastatic melanoma. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. N Engl J Med 2010 363 711 723 10.1056/NEJMoa1003466 20525992
8. Melanoma: new insights and new therapies. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H, J Invest Dermatol 2012 132 854 863 10.1038/jid.2011.421 22217739
9. Melanoma: from mutations to medicine. Tsao H, Chin L, Garraway LA, Fisher DE, Genes Dev 2012 26 1131 1155 10.1101/gad.191999.112 22661227
10. Melanoma in 2011: a new paradigm tumor for drug development. Eggermont AM, Robert C, Nat Rev Clin Oncol 2012 9 74 76 10.1038/nrclinonc.2011.201 22231762
11. Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Khattak M, Fisher R, Turajlic S, Larkin J, Ther Adv Med Oncol 2013 5 105 118 10.1177/1758834012466280 23450149
12. Novel targets in the treatment of advanced melanoma: New first-line treatment options (april). Culos KA, Cuellar S, Ann Pharmacother 2013 47 4 519 526 10.1345/aph.1R614 23548648
13. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, et al. Nature 2010 464 431 435 10.1038/nature08833 20130576
14. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R, Cell 2010 140 209 221 10.1016/j.cell.2009.12.040 20141835
15. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. Fremin C, Meloche S, J Hematol Oncol 2010 3 8 10.1186/1756-8722-3-8 20149254
16. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, Ricart AD, Clin Cancer Res 2010 16 1924 1937 10.1158/1078-0432.CCR-09-1883 20215549
17. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, et al. Neoplasia 2009 11 720 731 19649202
18. Improved survival with MEK inhibition in BRAF-mutated melanoma. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al. N Engl J Med 2012 367 107 114 10.1056/NEJMoa1203421 22663011
19. MEK and the inhibitors: from bench to bedside. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D, J Hematol Oncol 2013 6 27 10.1186/1756-8722-6-27 23587417
20. The therapeutic promise of the cancer stem cell concept. Frank NY, Schatton T, Frank MH, J Clin Invest 2010 120 41 50 10.1172/JCI41004 20051635
21. Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. Smalley KS, Herlyn M, Int J Cancer 2009 124 1245 1250 10.1002/ijc.24129 19089923
22. Tumor initiation in human malignant melanoma and potential cancer therapies. Ma J, Frank MH, Anticancer Agents Med Chem 2010 10 131 136 10.2174/187152010790909254 20184545
23. Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. Tomao F, Papa A, Rossi L, Strudel M, Vici P, Lo Russo G, Tomao S, J Experimental Clin Cancer Res: CR 2013 32 48 10.1186/1756-9966-32-48
24. A tumorigenic subpopulation with stem cell properties in melanomas. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M, Cancer Res 2005 65 9328 9337 10.1158/0008-5472.CAN-05-1343 16230395 (Pubitemid 41508000)
25. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, et al. Eur J Cancer 2007 43 935 946 10.1016/j.ejca.2007.01.017 17320377 (Pubitemid 46366698)
26. Identification and targeting of cancer stem cells. Schatton T, Frank NY, Frank MH, Bioessays 2009 31 1038 1049 10.1002/bies.200900058 19708024
27. Identification of cells initiating human melanomas. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, et al. Nature 2008 451 345 349 10.1038/nature06489 18202660
28. Efficient tumour formation by single human melanoma cells. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ, Nature 2008 456 593 598 10.1038/nature07567 19052619
29. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ, Cancer Cell 2010 18 510 523 10.1016/j.ccr.2010.10.012 21075313
30. Characterization of melanoma cells capable of propagating tumors from a single cell. Held MA, Curley DP, Dankort D, McMahon M, Muthusamy V, Bosenberg MW, Cancer Res 2010 70 388 397 10.1158/0008-5472.CAN-09-2153 20048081
31. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, et al. Nature 2010 466 133 137 10.1038/nature09161 20596026
32. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M, Cell 2010 141 583 594 10.1016/j.cell.2010.04.020 20478252
33. Selection of tumorigenic melanoma cells using ALDH. Boonyaratanakornkit JB, Yue L, Strachan LR, Scalapino KJ, LeBoit PE, Lu Y, Leong SP, Smith JE, Ghadially R, J Invest Dermatol 2010 130 2799 2808 10.1038/jid.2010.237 20739950
34. Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. Prasmickaite L, Engesaeter BO, Skrbo N, Hellenes T, Kristian A, Oliver NK, Suo Z, Maelandsmo GM, PLoS One 2010 5 10731 10.1371/journal.pone.0010731 20505780
35. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, Belloni B, Seifert B, Moch H, Dummer R, van den Broek M, Sommer L, Cancer Res 2011 71 8 3098 3109 10.1158/0008-5472.CAN-10-3997 21393506
36. Melanoma-initiating cells: a compass needed. Refaeli Y, Bhoumik A, Roop DR, Ronai ZA, EMBO Rep 2009 10 965 972 10.1038/embor.2009.184 19680286
37. From cancer stem cells to tumor maintenance in melanoma. Fukunaga-Kalabis M, Roesch A, Herlyn M, J Invest Dermatol 2011 131 1600 1604 10.1038/jid.2011.159 21654838
38. Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. Perego M, Tortoreto M, Tragni G, Mariani L, Deho P, Carbone A, Santinami M, Patuzzo R, Mina PD, Villa A, et al. J Invest Dermatol 2010 130 1877 1886 10.1038/jid.2010.69 20376064
39. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Iliopoulos D, Hirsch HA, Wang G, Struhl K, Proc Natl Acad Sci U S A 2011 108 1397 1402 10.1073/pnas.1018898108 21220315
40. The cancer stem cell: premises, promises and challenges. Clevers H, Nat Med 2011 17 313 319 21386835
41. Identification and expansion of the tumorigenic lung cancer stem cell population. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R, Cell Death Differ 2008 15 504 514 10.1038/sj.cdd.4402283 18049477 (Pubitemid 351267301)
42. Chemotherapy resistance of glioblastoma stem cells. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De Maria R, Cell Death Differ 2006 13 1238 1241 10.1038/sj.cdd. 4401872 16456578 (Pubitemid 43905604)
43. Identification and expansion of human colon-cancer-initiating cells. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R, Nature 2007 445 111 115 10.1038/nature05384 17122771 (Pubitemid 46067311)
44. EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. Sette G, Salvati V, Memeo L, Fecchi K, Colarossi C, Di Matteo P, Signore M, Biffoni M, D'Andrea V, De Antoni E, et al. PLoS One 2012 7 46891 10.1371/journal.pone. 0046891 23056514
45. Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Griewank KG, van de Nes J, Schilling B, Moll I, Sucker A, Kakavand H, Haydu LE, Asher M, Zimmer L, Hillen U, et al. Mod Pathol 2013 doi: 10.1038/modpathol.2013. 138
46. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, et al. Lancet Oncol 2012 13 782 789 10.1016/S1470-2045(12)70269-3 22805292
47. In-vivo transfection of pcDNA3.1-IGFBP7 inhibits melanoma growth in mice through apoptosis induction and VEGF downexpression. Chen RY, Chen HX, Lin JX, She WB, Jiang P, Xu L, Tu YT, J Exp Clin Cancer Res 2010 29 13 10.1186/1756-9966-29-13 20158915
48. Dynamic regulation of cancer stem cells and clinical challenges. Ni C, Huang J, J Clin Transl Oncol 2012 15 4 253 258
49. The clinical and therapeutic implications of cancer stem cell biology. Cheng L, Alexander R, Zhang S, Pan C-X, MacLennan GT, Lopez-Beltran A, Montironi R, Expert Rev Anticanc 2011 11 1131 1143
50. CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma. Lin Y, Zhong Y, Guan H, Zhang X, Sun Q, J Exp Clin Cancer Res 2012 31 59 10.1186/1756-9966-31-59 22762532
51. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Boasberg PD, Redfern CH, Daniels GA, Bodkin D, Garrett CR, Ricart AD, Cancer Chemother Pharmacol 2011 68 547 552 10.1007/s00280-011-1620-1 21516509
52. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, et al. Proc Natl Acad Sci U S A 2009 106 16281 16286 10.1073/pnas.0905653106 19805294
53. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, et al. Mol Cancer Ther 2011 10 325 335 10.1158/1535-7163.MCT-10-0788 21216927